R. Todd Joyce has been named senior vice president and chief financial officer of Watson Pharmaceuticals, effective immediately. Mr. Joyce succeeds Mark W. Durand, who left the company for personal reasons. Mr. Joyce has served as acting principal financial officer since July 27, 2009, when Mr. Durand took a leave of absence.

"I, the Board of Directors and the senior management team wish to thank Mark for his service to the Company. We appreciate this was a difficult decision for him, and wish him well in the future," said Paul Bisaro, Watson's president and chief executive officer. "We are fortunate that Todd has agreed to become our new CFO. Todd's financial expertise and his history within the organization will enable him to seamlessly perform these duties, and to continue the good work begun by Mark during his tenure. In addition, Todd's international experience will be important as we continue to expand globally, and particularly in the integration of Watson and Arrow Group following the anticipated close of the Arrow acquisition later this year."

Mr. Joyce joined the company in 1997 as corporate controller, and was named vice president, corporate controller and treasurer in 2001. Later, Mr. Joyce served as interim principal financial officer. Previously, he served as vice president of tax, and vice president of tax and finance at ICN Pharmaceuticals. Prior to ICN, Mr. Joyce served as a CPA for Coopers & Lybrand and Price Waterhouse.

News from our sister sites